ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Nuvalent Inc

Nuvalent Inc (NUVL)

123,50
-0,01
(-0,01%)
Fermé 01 Juillet 10:00PM
123,43
-0,07
(-0,06%)
Après les heures de négociation: 1:59AM

Nuvalent Inc (NUVL) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
123,50
( -0,01% )
Prix Achat
123,41
Prix Vente
123,85
Volume échangé
1 654 071
123,43 Fourchette du Jour 123,56
71,13 Plage de 52 semaines 123,69
Cap du marché
Clôture Veille
123,51
Ouverture
123,52
Dernière Transaction
33
@
123.85
Dernière heure de transaction
Volume financier
US$ 204 259 508
VWAP
123,489
Volume moyen (3 m)
US$ 2 115 687
Actions en circulation
78 997 915
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-20,43
Bénéfice par action (BPA)
-6,05
Chiffre d'affairess (LTM)
-
Bénéfice net (LTM)
-450,07M

À propos de Nuvalent Inc

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous ... Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
Cambridge, United States
Fondé
2026
Nuvalent Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker NUVL. Le dernier cours de clôture d'Nuvalent était de US$123,51. Au cours de la dernière année, les actions de Nuvalent ont été négociées dans une fourchette de prix de US$ 71,13 à US$ 123,69.

Nuvalent compte actuellement 78 997 915 actions en circulation. La capitalisation boursière d'Nuvalent est de US$9,76 milliard. Nuvalent a un ratio cours/bénéfice (ratio PE) de -20.43.

Flux d'options Nuvalent (NUVL)

Flux global

Haussier

Prime nette

41k

Calls / Puts

100,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

0,00%

NUVL Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.010.00809782168597123.49123.69123.411845832123.52427398CS
430.1932.354517200793.31123.6987.35466849121.41970007CS
1219.7719.0590957293103.73123.6987.32205239117.98223747CS
2621.921.5551181102101.6123.6987.31331446114.38031661CS
5243.955.150753768879.6123.6971.13924240107.62560527CS
15680.28185.74733919543.22123.6938.7863967189.80080713CS
260105.4582.32044198918.1123.697.0947365978.377362CS

NUVL - Frequently Asked Questions (FAQ)

What is the current Nuvalent Inc share price?
The current share price of Nuvalent Inc is US$ 123,50
How many Nuvalent Inc shares are in issue?
Nuvalent Inc has 78 997 915 shares in issue
What is the market cap of Nuvalent Inc?
The market capitalisation of Nuvalent Inc is USD 9,76B
What is the 1 year trading range for Nuvalent Inc share price?
Nuvalent Inc has traded in the range of US$ 71,13 to US$ 123,69 during the past year
What is the PE ratio of Nuvalent Inc?
The price to earnings ratio of Nuvalent Inc is -20,43
What is the registered address of Nuvalent Inc?
The registered address for Nuvalent Inc is One Broadway, Cambridge, Massachusetts, 02142
What is the Nuvalent Inc website address?
The website address for Nuvalent Inc is nuvalent.com
Which industry sector does Nuvalent Inc operate in?
Nuvalent Inc operates in the Biotechnology & Life Sciences sector

NUVL Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock